Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics
暂无分享,去创建一个
Hans-Leo Teulings | Michael P. Caligiuri | Charles E. Dean | H. Teulings | J. Lohr | M. Caligiuri | C. E. Dean | A. Niculescu | James B. Lohr | Alexander B. Niculescu
[1] Y. Kao Yang,et al. Risk of Extrapyramidal Syndrome in Schizophrenic Patients Treated with Antipsychotics: A Population‐based Study , 2007, Clinical pharmacology and therapeutics.
[2] J. Lohr,et al. Quantitative instrumental measurement of tardive dyskinesia: a review. , 1992, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[3] R. Regenthal,et al. D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. , 2005, International journal of clinical pharmacology and therapeutics.
[4] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.
[5] Gary Remington,et al. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.
[6] R. Mailman,et al. Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.
[7] L. Cronbach. Coefficient alpha and the internal structure of tests , 1951 .
[8] William J. Marks,et al. Deep Brain Stimulation Management: Abnormal Involuntary Movement Scale , 2010 .
[9] A. Seese,et al. Verkleinerung der Handschriftfläche und D2-Dopaminrezeptorblockade Ergebnisse unter Behandlung mit typischen und atypischen Neuroleptika , 2000, Der Nervenarzt.
[10] J. Arnt. Pharmacological differentation of classical and novel antipsychotics , 1998, International clinical psychopharmacology.
[11] Hans-Leo Teulings,et al. Digital recording and processing of handwriting movements , 1984 .
[12] F G Paas,et al. Effects of age and gender on discrete and reciprocal aiming movements. , 1996, Psychology and aging.
[13] Hermann-Josef Gertz,et al. Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs , 1999, Psychiatry Research: Neuroimaging.
[14] R. Mcquade,et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine , 2006, Psychopharmacology.
[15] B. Roth,et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. , 2006, CNS drug reviews.
[16] P. Korenblat,et al. A randomized double-blind trial , 2003 .
[17] H Wetzel,et al. Extrapyramidal Symptoms and their Relationship to Clinical Efficacy under Perphenazine Treatment* , 1991, Pharmacopsychiatry.
[18] G. Simpson,et al. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.
[19] D. Jeste,et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.
[20] G. Stelmach,et al. Parkinsonism Reduces Coordination of Fingers, Wrist, and Arm in Fine Motor Control , 1997, Experimental Neurology.
[21] F. Tarazi,et al. Effects of Newer Antipsychotics on Extrapyramidal Function , 2002, CNS Drugs.
[22] John L. Bradshaw,et al. Kinematic analysis of handwriting movements in Schizophrenic patients , 1997, Biological Psychiatry.
[23] Jeffrey A. Lieberman,et al. Extrapyramidal side-effects of antipsychotics in a randomised trial , 2008, British Journal of Psychiatry.
[24] R. Tandon,et al. Extrapyramidal Side Effects of Antipsychotic Treatment: Scope of Problem and Impact on Outcome , 2002, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[25] S. Marder,et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials , 2003, Schizophrenia Research.
[26] R. Kessler. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism? , 2007, The American journal of psychiatry.
[27] J. Kane,et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. , 2003, The Journal of clinical psychiatry.
[28] T. Barnes. A Rating Scale for Drug-Induced Akathisia , 1989, British Journal of Psychiatry.
[29] Hans-Leo Teulings,et al. Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism. , 2006, Human movement science.
[30] Haase Hj. Extrapyramidal modification of fine movements: a "conditio sine qua non" of the fundamental therapeutic action of neuroleptic drugs. , 1961 .
[31] D. Jeste,et al. Antipsychotic-Induced Movement Disorders in the Elderly , 2000, Drugs & aging.
[32] R A Abrams,et al. Optimality in human motor performance: ideal control of rapid aimed movements. , 1988, Psychological review.
[33] Hans-Leo Teulings,et al. Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. , 2009, Human movement science.
[34] P. Weiden. EPS Profiles: The Atypical Antipsychotics: Are Not All the Same , 2007, Journal of psychiatric practice.